Drugs / Depo-subQ 104
Trials 0
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT03700658 Comparator | Jan 2019 → Oct 2020 | — | Teva Branded Pharmaceutical Products R&D, Inc. | Completed | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Depo-subQ 104 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03700658 ↗ |
| Route | Subcutaneous | “Participants will receive Depo-subQ 104 (medroxyprogesterone acetate injectable suspension; 104 mg/0.65 mL) SC injection” NCT03700658 ↗ |